Pharsight

Procysbi patents expiration

PROCYSBI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9925157 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(2 years from now)

US9925158 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(2 years from now)

US9925156 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925157 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(2 years from now)

US9925158 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(2 years from now)

US8129433 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(2 years from now)

US9925156 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(2 years from now)

US9192590 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(2 years from now)

US9198882 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(2 years from now)

US9198882

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(3 years from now)

US9925156

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(3 years from now)

US9925158

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(3 years from now)

US9925157

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(3 years from now)

US9192590

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jul, 2027

(3 years from now)

US8026284 HORIZON Enterically coated cystamine, cysteamine and derivatives thereof
Sep, 2027

(3 years from now)

US8026284

(Pediatric)

HORIZON Enterically coated cystamine, cysteamine and derivatives thereof
Mar, 2028

(3 years from now)

US9233077 HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Jun, 2034

(10 years from now)

US9173851 HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Jun, 2034

(10 years from now)

US9233077

(Pediatric)

HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Dec, 2034

(10 years from now)

US9173851

(Pediatric)

HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Dec, 2034

(10 years from now)

US10548859 HORIZON Methods for storing Cysteamine formulations and related methods of treatment
Aug, 2036

(12 years from now)

US10143665 HORIZON Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(12 years from now)

US10328037 HORIZON Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(12 years from now)

US10905662 HORIZON Methods for storing cysteamine formulations and related methods of treatment
Aug, 2036

(12 years from now)

US10905662

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(12 years from now)

US10143665

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(12 years from now)

US10328037

(Pediatric)

HORIZON Methods for storing cysteamine formulations and related methods of treatment
Feb, 2037

(12 years from now)

US10548859

(Pediatric)

HORIZON Methods for storing Cysteamine formulations and related methods of treatment
Feb, 2037

(12 years from now)

Procysbi is owned by Horizon.

Procysbi contains Cysteamine Bitartrate.

Procysbi has a total of 28 drug patents out of which 0 drug patents have expired.

Procysbi was authorised for market use on 14 February, 2020.

Procysbi is available in capsule, delayed release;oral, granule, delayed release;oral dosage forms.

Procysbi can be used as management of nephropathic cystinosis by administering a total daily dose in two divided doses.

The generics of Procysbi are possible to be released after 16 February, 2037.

Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) Dec 22, 2024
Pediatric Exclusivity(PED) Jun 22, 2025
M(M-216) Dec 22, 2020

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 14 February, 2020

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: GRANULE, DELAYED RELEASE;ORAL; CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of PROCYSBI before it's drug patent expiration?
More Information on Dosage

PROCYSBI family patents

Family Patents